Achilles Therapeutics Investor Relations Material

Achilles Therapeutics plc is a biopharmaceutical company based in the United Kingdom, focused on developing precision T cell therapies targeting cancer. Using its proprietary platform, Achilles designs therapies that target clonal neoantigens—unique markers on tumor cells—enabling a personalized approach to treatment. The company’s therapeutic programs are primarily aimed at treating solid tumors, including lung and melanoma cancers. The company is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.